Viatris

VTRS Health Care Market cap $19.1B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026

Revenue$3.76B +5% year over year

Gross profit$1.46B 39% margin

Operating profit$0.01B 0% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.76	100%	+5%
Cost of revenue	−2.30	61%
Gross profit	1.46	39% margin	+2pp
R&D	−0.25	7%	+1pp
SG&A	−1.14	30%	+4pp
Other	−0.07	2%
Operating profit	0.01	0% margin	−6pp

The table stops at operating profit: the source reports a net profit of exactly zero, which no company earns, and the lines below it are what was used to reach that zero.

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.52	100%	+8%
Brands	2.33	66%	+10%
Lipitor	0.46	13%	+19%
Other revenue	0.27	8%
Lyrica	0.12	3%	+7%
Creon	0.10	3%	+18%
Viagra	0.10	3%
Zoloft	0.07	2%	+21%
Celebrex	0.07	2%
Cost of revenue	−2.36	67%
Gross profit	1.16	33% margin	−3pp
R&D	−0.25	7%	+0pp
SG&A	−0.93	26%	−3pp
Other	−0.06	2%	+0pp
Operating profit	−0.08	−2% margin	+86pp

The table stops at the operating loss: the source reports a net profit of exactly zero, which no company earns, and the lines below it are what was used to reach that zero.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.70	100%	+5%
Brands	2.35	63%	+8%
Other revenue	0.43	12%
Lipitor	0.38	10%	+6%
Norvasc	0.18	5%	+5%
Lyrica	0.12	3%	−6%
Viagra	0.10	3%	+18%
Epi pen auto injectors	0.08	2%	+8%
Yupelri	0.07	2%	+6%
Cost of revenue	−2.56	69%
Gross profit	1.15	31% margin	−3pp
SG&A	−1.03	28%	−2pp
Other	−0.31	8%	+0pp
Operating profit	−0.19	−5% margin	+0pp

The table stops at the operating loss: the source reports a net profit of exactly zero, which no company earns, and the lines below it are what was used to reach that zero.

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.76	100%	+0%
Brands	2.44	65%	+3%
Lipitor	0.40	11%	+5%
Other revenue	0.35	9%
Epi pen auto injectors	0.16	4%	+28%
Lyrica	0.13	3%	−3%
Influvac	0.13	3%	+3%
Creon	0.09	3%	+10%
Celebrex	0.07	2%	−1%
Cost of revenue	−2.39	64%
Gross profit	1.37	36% margin	−2pp
R&D	−0.25	7%	+1pp
SG&A	−0.89	24%	−3pp
Other	−0.06	1%	+0pp
Operating profit	0.18	5% margin	−1pp

The table stops at operating profit: the source reports a net profit of exactly zero, which no company earns, and the lines below it are what was used to reach that zero.

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.58	100%	−6%
Brands	2.29	64%
Lipitor	0.39	11%
Other	0.29	8%
Norvasc	0.18	5%
Epi pen auto injectors	0.14	4%
Lyrica	0.13	3%
Viagra	0.10	3%
Celebrex	0.07	2%
Cost of revenue	−2.25	63%
Gross profit	1.33	37% margin	−1pp
R&D	−0.22	6%	+1pp
SG&A	−0.88	25%	−1pp
Operating profit	0.23	7% margin	+13pp

The table stops at operating profit: the source reports a net profit of exactly zero, which no company earns, and the lines below it are what was used to reach that zero.

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

The balance sheet, capital flow, debt schedule and capital structure open with a free account.

Quarter by quarter

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026 Operating margin 0% Net profit –	Apr 1 – Jun 30, 2026	Aug 6, 2026	$3.76B	+5%	0%	–	–
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 7, 2026 Operating margin −2% Net profit –	Jan 1 – Mar 31, 2026	May 7, 2026	$3.52B	+8%	−2%	–	–
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 26, 2026 Operating margin −5% Net profit –	Oct 1 – Dec 31, 2025	Feb 26, 2026	$3.70B	+5%	−5%	–	–
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 6, 2025 Operating margin 5% Net profit –	Jul 1 – Sep 30, 2025	Nov 6, 2025	$3.76B	+0%	5%	–	–
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 7, 2025 Operating margin 7% Net profit –	Apr 1 – Jun 30, 2025	Aug 7, 2025	$3.58B	−6%	7%	–	–

Financial health

Quarter by quarter

New results in your inbox